The DOI matches its Crossref record; 413 of the 413 references it cites were found in a registry or an index; none of the 275 sources its claims cite is checked for support yet.
In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges
Open accessAbstract
Great needs always motivate the birth and development of new disciplines and tools. Here we propose in vitro BioTransformation (ivBT) as a new biomanufacturing platform, between the two dominant platforms—microbial fermentation and enzymatic biocatalysis. ivBT mediated by in vitro synthetic enzymatic biosystems (ivSEBs) is an emerging biomanufacturing platform for the production of biocommodities (i.e., low-value and bulk biochemicals). ivSEB is the in vitro reconstruction of artificial (non-natural) enzymatic pathways with numerous natural enzymes, artificial enzymes, and/or (biomimetic or natural) coenzymes without living cell’s constraints, such as cell duplication, basic metabolisms, complicated regulation, bioenergetics, and so on. The two great needs (i.e., food security and the carbon-neutral renewable energy system) have motivated the birth and development of ivBT. Food security could be addressed by making artificial food from nonfood lignocellulose and artificial photosynthesis for starch synthesis from CO2. The carbon-neutral renewable energy system could be addressed by the construction of the electricity-hydrogen-carbohydrate cycle, where starch could be a high density of hydrogen carrier (up to 14.8% H2 wt/wt) and an electricity storage compound (greater than 3000 Wh/kg). Also, ivBT can make a number of biocommodities, such as inositol, healthy sweeteners (e.g., D-allulose, D-tagatose, D-mannose), advanced biofuels, polymer precursors, organic acids, and so on. The industrial biomanufacturing of the first several biocommodities (e.g., myo-inositol, D-tagatose, D-mannose, and cellulosic starch) would wipe off any prejudice and doubt on ivBT. Huge potential markets of biocommodities with more than tens of trillions of Chinese Yuan would motivate scientists and engineers to address the remaining technical challenges and develop new tools within the next decade.
Overview
CoChat Summary
TL;DR
The paper defines in vitro BioTransformation (ivBT) as a third biomanufacturing platform using in vitro synthetic enzymatic biosystems (ivSEBs), positioned between microbial fermentation and enzymatic biocatalysis, and aimed at biocommodities. It argues ivBT can achieve near-theoretical yields, low energy consumption, and high volumetric productivity, with examples including inositol, rare sugars, 1,3-propanediol, isobutanol, artificial starch, and high-yield hydrogen.
Key findings
- ivSEBs can exceed microbial limits: an ivSEB can generate 12 moles of H2 from one glucose unit of starch and water, whereas anaerobic hydrogen-producing microorganisms are limited to no more than 4 H2 per glucose (Thauer limit); starch is described as a hydrogen carrier up to 14.8% H2 wt/wt dry and an electricity storage compound greater than 3000 Wh/kg.
- Industrial/commercial examples: starch-to-inositol is described as the first ivBT bioproduct, with a factory producing up to 10,000 metric tons yearly and operation in 60,000-L bioreactors; Bonumose claimed completion of a 1,000-tonne/year D-tagatose factory; artificial starch from CO2 reached 22 nanomoles CO2 per minute per milligram of total catalyst, about 8.5 times that of maize.
- Other reported yields include glycerol-to-1,3-propanediol at approximately 0.95 mol/mol, in vitro isobutanol at 53% yield even in the presence of 4% isobutanol, and L-lactate at 90% yield; enzyme production costs are cited as low as 100 CNY per kg dry weight for secretory enzymes and 250–300 CNY per kg for intracellular recombinant enzymes.
- The paper projects huge potential markets for biocommodities, more than tens of trillions of Chinese Yuan, and lists advantages such as near-theoretical product yield, low energy consumption, high volumetric productivity, and better tolerance of toxic compounds than microbes.
Methods
- Design: review/perspective article that proposes definitions, design principles, and a classification of ivBT and ivSEB, and compares ivBT with cascade enzyme biocatalysis and cell-free protein biosynthesis.
- Data or sample: no new experimental study is reported; the paper synthesizes cited literature, patents, and industrial examples, including inositol, rare sugars, 1,3-propanediol, isobutanol, artificial starch, and hydrogen.
- Main analysis: conceptual synthesis, pathway descriptions, a comparison table, case studies, and discussion of supporting technologies and remaining challenges.
Limitations
- Stated: remaining technical challenges include low-cost production of oxygen-sensitive enzyme complexes (e.g., hydrogenase, nitrogenase, CO2 reductase), high coenzyme cost, in vitro ATP regeneration, and scale-up/immobilization issues.
- Evident: as a review/perspective, it reports no primary data or systematic review methodology; many market sizes, cost projections, and feasibility claims are predictions or hypotheses rather than demonstrated outcomes.
- Evident: some industrial claims are company claims (e.g., the 1,000-tonne tagatose plant), and the paper itself notes external doubts about the economic feasibility of cellulose-to-starch, quoting Arnold and Tyner that “whether the process is economically feasible overall is the big question.”
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The development cycle of ivBT for biomanufacturing, modified from Ref. [20].](/paper-figures/88fde35e9dce4c27b26633ac2a088465/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-2.png)





![Figure 8 Schematic presentation of the in vitro synthetic enzymatic pathway for the production of 1,3-propanediol from glycerol, modified from Ref. [237]. Enzymes are GDHT (glycerol dehydratase), PDH (NADPH-dependent propanediol dehydrogenase), and SHI (soluble hydrogenase I) that is four-subunit cytoplasmic hydrogenase from P. furious .](/paper-figures/d6e8154c0477402eba5db19b055803fe/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-8.png)
![Figure 9 Schematic presentation of the in vitro ATP-free synthetic enzymatic pathways for the production of isobutanol [54] and lactate [245]. The enzymes are GDH (glucose dehydrogenase), DHAD (dihydroxy acid dehydratase), AIDH (glyceraldehyde dehydrogenase), KDGA (2-keto3-desoxygluconate aldolase), ALS (acetolactate synthase), KARI (ketol-acid reductor-isomerase), KDC (2-ketoacid decarboxylase), ALD (alcohol dehydrogenase), LDH (lactate dehydrogenase), and MDH (malate dehydrogenase) [246].](/paper-figures/e31a37e5c7a54f1eb20624d8b257fc90/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-9.png)
![Figure 10 Schematic presentation of the in vitro coenzyme-free synthetic enzymatic pathway for the production of synthetic amylose, ethanol by anaerobic ethanol-producing microorganism [50], and microbial protein by aerobic fermentation [51]. The enzymes are EG, endoglucanase; CBH, cellobiohydrolase; CBP, cellobiose phosphorylase; and PGP, potato α-glucan phosphorylase.](/paper-figures/288f3bad8d084cde9d2d832d48ae2c41/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-10.png)
![Figure 11 Schematic presentation of the in vitro methanol-to-starch enzymatic pathway [53]. Central enzymes are AOX (alcohol oxidase), FIS (formolase), DAK (dihydroxyacetone kinase, TIM (triose phosphate isomerase), ALD (fructose-bisphosphate aldolase), FBP (fructose bisphosphatase), PGI (phosphoglucose isomerase), PGM (phosphoglucomutase), AGP (ADP-glucose pyrophosphorylase), SS (starch synthase) and three supplementary enzymes are CAT (catalase), PPK (polyphosphate kinase), and PPA (pyrophosphatase).](/paper-figures/ab168fb42de548659ca8542005fd1080/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-11.png)
![Figure 12 Schematic presentation of the in vitro synthetic enzymatic pathways for the production of high-yield hydrogen from starch and water ( A ) [47,48,108] and four artificial ETCs converting reduced power to hydrogen ( B-E ). The enzymes are αGP, PGM, G6PDH (glucose 6-phosphate dehydrogenase), 6PGL (6-phosphogluconolactonase), 6PGDH (6-phosphogluconate dehydrogenase), RPI (ribose 5-phosphate isomerase), RPE (ribulose-5-phosphate 3-epimerase), TK (transketolase), TAL (transaldolase), TIM, (triose phosphate isomerase), ALD (fructose-bisphosphate aldolase), FBP (fructose bisphosphatase), PGI, SHI, NROR (NADPH rubredoxin oxidoreductase), and DI (diaphorase). The metabolites are: g1p, glucose-1-phosphate; g6p, glucose-6-phosphate; ru5p, ribulose 5-phosphate; x5p, xylulose 5-phosphate; r5p, ribose 5-phosphate; s7p, sedoheptulose 7-phosphate; g3p, glyceraldehyde 3-phosphate; e4p, erythrose 4-phosphate; dhap, dihydroxacetone phosphate; fdp, fructose-1,6diphosphate; f6p, fructose 6-phosphate.](/paper-figures/ee5bbe415c984696a92a97cf6e53fc6e/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-12.png)
![Figure 13 Schematic presentation of the starch-centered carbon-neutral economy [29,52], where starch is a high-density hydrogen carrier, an electricity storage compound, food/feed source and a bioplastic component. In it, ivBT would play a central role in artificial photosynthesis for starch synthesis [53] and reverse artificial photosynthesis for production of hydrogen [47,252] or electricity [30,52,67].](/paper-figures/8b31a49786ce44d38ad8aa94abc2820d/in-vitro-biotransformation-ivbt-definitions-opportunities-and-challenges-figure-13.png)
Verification
Claims the paper makes
0 Valid · 13 Not valid · 157 Not checked · 66 Own results and interpretations
In the paper
“The proof-of-concept experiment obtained a 53% isobutanol yield even in the presence of 4% isobutanol [54], suggesting that ivSEB can tolerate organic solvents far better than cellular membranes.”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 3.4. Isobutanol and Organic Acids
What the sources say
- Not matchedcites [54]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“In 2023, the same team demonstrated further improvement in the biosynthesis of sugars from CO2 and hydrogen [55].”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 3.5. Artificial Starch
What the sources say
- Not matchedcites [55]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Via directed evolution, the best mutant had a 7200-fold longer half-life at 55 ° C than the wild-type PPGK [89].”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 4.1. Collection of Ultra-stable Enzymes
What the sources say
- Not matchedcites [89]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Also, Prof. Zhang found out a novel way to enzymatically transform D-xylose to L-Arabinose (a healthy natural sweeteners with more than 50 billion CNY) so to increase economical viability of new biorefining of agricultural residues to new food/feed sources.”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 3.5. Artificial Starch
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Zhang's team increased volumetric productivity of hydrogen by 1000-fold by using kinetic modeling to identify the rate-limiting steps [169,262], optimization of enzyme loadings and the use of high-activity enzymes [108].”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 3.6. Green Hydrogen
What the sources say
- Not matchedcites [169]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [262]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [108]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
101 more claims
Create a free account to see all 236 claims and every source verdict.
- Probably not a substantial claim. 74
- It may state two separate claims as one. 88
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Microbes may have 5 6 = 625 combinations because each layer is linked with other layers.”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 2.4. Biomanufacturing Advantages
Reported 625 · recomputed 15625
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 2.3. Comparison with Other Seemingly-like Technologies
“whose market size ceiling could be up to 500 million CNY”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 2.3. Comparison with Other Seemingly-like Technologies
“10 million to 100 million CNY (maximum)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 2.3. Comparison with Other Seemingly-like Technologies
“The former aims at biomanufacturing of biocommodities whose minimum mass is 10,000 metric tons, whose market size is greater than 500 million CNY”
§ In Vitro BioTransformation (ivBT): Definitions, Opportunities, and Challenges > 2.3. Comparison with Other Seemingly-like Technologies
“Individual product market size 100 million CNY (minimum) to tens of trillions CNY (hydrogen)”
Citations
Cites
Items 401–413 of 413
The discovery of carbon dioxide fixation in mammalian tissues
Krebs, H. A. (1974) · Molecular and Cellular Biochemistry · doi:10.1007/bf01874176 · Cited by 9
Professor Daniel I.C. Wang: A legacy of education, innovation, publication, and leadership
Afeyan, N. B., & Cooney, C. L. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21078 · Cited by 9
Zhang, Y., Muhammad, F., & Wei, H. (2021) · ChemBioChem · doi:10.1002/cbic.202100049 · Cited by 9
A simple method for in-house Pfu DNA polymerase purification for high-fidelity PCR amplification
Sankar, P. S., Citartan, M., Siti, A. A., Skryabin, B. V., Rozhdestvensky, T. S., Khor, G. H., & Tang, T. (2019) · Iranian Journal of Microbiology · doi:10.18502/ijm.v11i2.1085 · Cited by 9
Stech, M., Rakotoarinoro, N., Teichmann, T., Zemella, A., Thoring, L., & Kubick, S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1406-8_9 · Cited by 6
ATP regeneration by thermostable ATP synthase
Nam, K. Y., Struck, D. K., & Holtzapple, M. T. (1996) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19960805)51:3<305::aid-bit6>3.0.co;2-h · Cited by 5
Remarks on Computational Method for Identifying Acid and Alkaline Enzymes
Li, H., Du, H., Wang, X., Gao, P., Liu, Y., & Lin, W. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200617170826 · Cited by 4
Rieckenberg, F., Götz, K., Hilterhaus, L., Liese, A., & Zeng, A. (2014) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-014-1225-2 · Cited by 3
Lake, F. (2019) · BioTechniques · doi:10.2144/btn-2019-0061 · Cited by 3
Aminomutation catalyzed by CO 2 self-sufficient cascade amino acid decarboxylasesPreprint
Song, Z. P., Li, Y., Li, Y., Cui, X., Zhong, J., & Zhang, Y. ‐. P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.12.552924 · Cited by 2
Li, Y., Shi, T., Han, P., & You, C. (2022) · ACS Catalysis · doi:10.1021/acscatal.2c06070 · Cited by 1
Self-citationEnzymatic Synthesis of Oligosaccharides
Zhang, J., Shao, J., Kowal, P., & Wang, P. G. (2005) · Carbohydrate‐Based Drug Discovery · doi:10.1002/3527602437.ch6
Heckmann, C. M., & Paradisi, F. (2020) · ChemCatChem · doi:10.1002/cctc.202001724
Research works printed but not linked: 11
- 14. Zhang Y-HPJ. Remembering Professor Daniel IC Wang's contribution to biorefining and my opinions in perspective of biorefining. Syn. Biol. J. 2021, 2, 497-508.
- 36. National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Government-University-Industry Research Roundtable. The Fourth Industrial Revolution: Proceedings of a Workshop-in Brief; National Academies Press: Washington, DC, USA; 2017.
- 52. Song Y, Wu R, Wei X, Shi T, Li Y, You C, et al. Advances in a new energy system based on electricity-hydrogen-carbohydrate cycle. Chin. J. Biotechnol. 2022, 38, 4081-4100.
- 128. Michels P, Rosazza J. The evolution of microbial transformations for industrial applications. SIM News 2009, 2009, 36-52.
- 155. Swartz JR. Cell-free bioprocessing. Chem. Eng. Prog. 2013, 2013, 40-45.
- 184. Colodny L, Hoffman RL. Inositol-clinical applications for exogenous use. Altern. Med. Rev. 1998, 3, 432-447.
- 201. Men Y, Zhu Y, Guan Y, Zhang T, Izumori K, Sun Y. Screening of food-grade microorganisms for biotransformation of D-tagatose and cloning and expression of L-arabinose isomerase. Sheng Wu Gong Cheng Xue Bao 2012, 28, 592-601.
- 247. Choi C. Could Wood Feed the World? Science 2013. Available online: https://www.sciencemag.org/news/2013/2004/could-wood-feed-world (accessed on 20 May 2023).
- 264. Rollin JA, Ye XH, Martin dCJS, Adams MWW, Zhang Y-HP. Novel hydrogen detection apparatus along with bioreactor Systems. In Bioreactor Engineering Research and Industrial Applications II; Springer: Berlin/Heidelberg, 2016.
- 266. Berezina OV, Zverlov VV, Lunina NA, Chekanovskaya LA, Dubinina EN, Liebl W, et al. Gene and properties of thermostable 4-α-glucanotransferase of Thermotoga neapolitana. Mol. Biol. 1999, 33, 801-806.
- 340. Stiefel EI, George GN. Ferredoxins, hydrogenases, and nitrogenases: Metal-sulfide proteins. In Bioinorganic Chemistry; University Science Books: Melville, NY, USA, 1994; pp. 365-453.
Cited by
Recent Advances on Biological Production of a Functional Low-Calorie Sugar d -Tagatose
Fan, L., Chen, J., Chen, Y.-L., Pečar, D., Ding, J., Ni, D., & Mu, W. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c04610 · Cited by 25
Martínez, J. B. G., Behr, J., & Denkenberger, D. (2024) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2024.104609 · Cited by 18
Yang, X. N., Zhang, Y., & Zhao, G. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108294 · Cited by 11
Engineering Escherichia coli Pyruvate Metabolism to Generate Noncanonical Reducing Power
Aspacio, D., Luu, E., Worakaensai, S., Cui, Y., Maxel, S., King, E. J., Hagerty, R., Chu, A., Minn, D., Siegel, J. B., et al. (2024) · ACS Catalysis · doi:10.1021/acscatal.4c02131 · Cited by 9
Ning, X., Li, F. L., Wei, X., Zhu, Z., & You, C. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00447 · Cited by 9
Self-citation
Metadata
- Authors
- P. Job Zhang, Y.-H., Zhu, Z., You, C., Zhang, L., & Liu, K.
- Affiliations
- Chinese Academy of Sciences (CN)
- Venue
- Synthetic Biology and Engineering
- Publisher
- SCIE Publishing Limited
- Published
- 2023
- Volume
- 1
- Issue
- 2
- Pages
- 10013-10013
- ISSN
- 2958-9045 (ISSN-L)
- 2958-9053
- OpenAlex
- W4386901156
- Semantic Scholar
- e8da9e68b06b9f787719b2d340eca39a95fc085f
- Cited by
- 38
- References
- 408
- Citations by year
- 2026: 7 · 2025: 21 · 2024: 9 · 2023: 1
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Synthetic biology and engineering (publishedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (32271544)
- National Key Research and Development Program of China (2022YFA0912300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme Catalysis and Immobilization
- Physical Sciences › Engineering › Biomedical Engineering › Biofuel production and bioconversion
- Keywords
- in vitro biotransformation, bioproduction, artificial photosynthesis, hydrogen storage, myo-inositol, D-tagatose, D-mannose, food security
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.